Menu Search
Equities

Mayne Pharma Group Ltd

MAYNF:PKC

Mayne Pharma Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.46
  • Today's Change0.00 / 0.00%
  • Shares traded314.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

  • Revenue in AUD (TTM)278.45m
  • Net income in AUD-258.82m
  • Incorporated2005
  • Employees900.00
  • Location
    Mayne Pharma Group Ltd1538 Main North RdADELAIDE 5106AustraliaAUS
  • Phone+61 88209-2666
  • Fax+61 88281-0284
  • Websitehttp://www.maynepharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.